NCT06524804View on ClinicalTrials.gov

A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid Tumors

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

October 18, 2024

Study Completion Date

October 18, 2024

Conditions
Solid Tumor, Adult
Interventions
DRUG

BY101298 Capsules

An oral DNA-PK Inhibitor

RADIATION

palliative radiotherapy

Undergo palliative radiotherapy

DRUG

BY101298 Capsules

An oral DNA-PK Inhibitor

RADIATION

curative radiotherapy

Undergo curative radiotherapy

Trial Locations (1)

250117

Cancer Hospital Affiliated to Shandong First Medical University / Shandong Cancer Research Institute / Shandong Cancer Hospital, Jinan

Sponsors
All Listed Sponsors
lead

Chengdu Baiyu Pharmaceutical Co., Ltd.

INDUSTRY

NCT06524804 - A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid Tumors | Biotech Hunter | Biotech Hunter